Ercc1 And Xrcc1 As Prognostic Biomarkers For Early Her2-Positive Breast Cancer

e12562Background: A few prognostic factors are used to make decision on breast cancer (BC) treatment. Researches to identify novel prognostic and predictive factors are still actual. Two DNA repair proteins were studied as prognostic markers for patients with early HER2-positive BC, who received or not adjuvant trastuzumab (T). Methods: 103 patients with HER2+ BC, I-IIIa stage, treated with surgery in 3 Russian Cancer Centers . from 2002 to 2007 were included in analysis. Adjuvant treatment with trastuzumab was performed for 58 patients (56,3%) only. In all cases expression of ERCC1 and XRCC1 were immunohistochemistry studied. Patient characteristics at the time of BC diagnosis, expression of biomarkers, treatment options and their associations with overall survival (OS) and progression free survival (PFS) were evaluated by Kaplan-Meier curves, log-rank tests, and Cox proportional hazard models. Results: 8-years PFS was 74,4%: 80,3 % for patients received adjuvant trastuzumab vs 60,9 % for patient without...